|
Ocular Therapeutix Inc (OCUL) |
|
Ocular Therapeutix Inc
OCUL's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Ocular Therapeutix Inc growth rates, revenue grew
by 8.26 % in II. Quarter 2024 from the same quarter a year ago.
Ranking at No. 1039
Major Pharmaceutical Preparations industry recorded
growth of revenues by 5.17 %
Ocular Therapeutix Inc net loss increased from $-21 millions, to $-44 millions in II. Quarter 2024,
• More on OCUL's Growth
|
|
Ocular Therapeutix Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 4.13 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 26.54.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.77.
• More on OCUL's Valuation
|
|
|
|
|
Ocular Therapeutix Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 4.13 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 26.54.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.77.
Ocular Therapeutix Inc Price to Book Ratio is at 4.29 lower than Industry Avg. of 85.07. and higher than S&P 500 Avg. of 0
• More on OCUL's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com